Medical Health & Life Science Research News

Recent research: Europe's plasma fractionation market is poised to touch USD 7.04 bn by 2021

Europe Plasma Fractionation Market By Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Pulmonology, Immunology) End User (Hospitals, Clinical Research Laboratories) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2016–2021)

- Advertising -

The Europe Plasma Fractionation Market was worth USD 5.24 billion in 2016 and is projected to be growing at a CAGR of 6.10%, to touch USD 7.04 billion by 2021. Plasma Fractionation consists of screening ad fractionating procedure in which the blood is split into its constituents of the plasma and RBCs, WBCs and platelets.

The plasma is studied for various deficiencies and replaced, or treatment is prescribed.

Browse Market data tables and in-depth TOC of the Europe Plasma Fractionation Market to 2021 @ www.marketdataforecast.com/market-…tion-market-2839/

Plasma is a necessary constituent of blood as it constitutes about 55% blood by volume and carries more than a thousand proteins and other substances like electrolytes, hormones which are required for the optimal function of the human body.

- Advertising -

Albumin is one of the major proteins which is replaced and also used to compensate during plasma exchange.

The growth of the Europe Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, growing incidence of Alpha-1 Antitrypsin deficiency and the rising use of immunoglobulins. Further, increasing aging population with related blood related ailments is set to promote market growth.

However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the major constraints of market growth.

Free sample of the report is available @ www.marketdataforecast.com/market-…39/request-sample

The Europe Plasma Fractionation Market is segment on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors.

Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.

The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy.  Europe holds the second position in terms of market share globally.

There is potential for market growth due to the presence of some untapped markets coupled with the rising frequency of blood related disorders. Rising elderly population with consequent blood disorders is also a contributor to market growth in this region.

Inquire report @ www.marketdataforecast.com/market-…rket-2839/inquire

The important players in the Europe Plasma Fractionation market are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...